Liposarcoma

P2, N=75, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

These findings highlight the clinical relevance of immune infiltration in retroperitoneal DDLPS and LMS. Moreover, they support the rationale for further exploration of the immune architecture for prognostic biomarkers and development of targeted immunotherapeutic strategies to improve the clinical outcomes of the patients.

P2/3, N=140, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026

This case highlights the diagnostic challenge of rare sarcomas presenting with serosal effusions and emphasizes the importance of integrating cytopathological, radiological, and molecular testing for accurate diagnosis and optimal management. Preventing misdiagnosis of this tumor as other histological subtypes is of great clinical significance, while IHC features and FISH can provide important clues for its accurate diagnosis.

Continued progress in biomarker-driven strategies and rational combination therapies is expected to further refine personalized treatment approaches and improve outcomes for patients with advanced liposarcoma.

In this review, we discuss the biology of MDM2 as an oncogene and summarize the current literature on MDM2 gene amplification in surgical pathology. We further outline the available diagnostic methods for assessing MDM2 status and highlight the potential diagnostic, prognostic, and therapeutic implications of this alteration.

Patients with DDLPS treated in US community settings are heterogeneous in terms of demographic and clinical characteristics, biomarker testing, treatment, and outcomes. The relatively poor survival rates suggest an unmet need for better therapeutics.

In conclusion, PATZ1 IHC is moderately sensitive and specific for PATZ1-rearranged sarcomas, and it may be a helpful diagnostic marker for this challenging tumor. While most tumors with morphologic overlap with PATZ1-rearranged sarcomas are negative for PATZ1 by IHC, expression in a subset of myoepithelial tumors and rhabdomyosarcomas represents a potential diagnostic pitfall.

In this report, we describe three Mullerian adenosarcomas with extrauterine presentation, all exhibiting extensive sarcomatous overgrowth and MDM2 amplification. These tumors underscore the critical importance of integrating clinical history, comprehensive tissue sampling, detailed morphologic evaluation, and molecular analysis to establish an accurate diagnosis.

While brigimadlin showed activity in this patient population, the median PFS with doxorubicin was substantially longer than anticipated and the primary endpoint of PFS was not met. The safety profile of brigimadlin also did not appear to be more manageable than that of doxorubicin. The translational results will guide future clinical investigations of MDM2-p53 antagonists.

P2, N=33, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027

In conclusion, our multi-omics analysis identifies HMGA2 fusion as a promising diagnostic and prognostic biomarker for DDLPS with rhabdomyosarcomatous differentiation. The comprehensive molecular and immune landscape of this tumor subtype not only deepens our understanding of its pathophysiology but also provides critical insights for future precision medicine strategies.